Predicting Blood Pressure Control Failure and Evaluating Treatment Effectiveness in Hypertensive Patients

Operational, Clinical, and Predictive Insights from Hypertensive Patient Data

Executive Overview

Hypertension remains one of the leading contributors to cardiovascular morbidity and mortality globally, with poor blood pressure (BP) control significantly increasing the risk of stroke, heart failure, chronic kidney disease, and other cardiovascular complications. Despite the availability of multiple antihypertensive therapies, a substantial proportion of patients fail to achieve adequate BP control due to varying clinical, behavioural, and treatment-related factors.

This project was conducted to evaluate predictors of blood pressure control failure at 3-month follow-up and to assess the effectiveness of antihypertensive medications in patients with specific comorbidity profiles.

Using hypertensive patient data, the analysis focused on identifying:

• Clinical predictors associated with BP control failure
• Treatment effectiveness patterns across patient subgroups
• High-risk patient populations requiring earlier intervention
• Opportunities for improved hypertension management strategies

The analysis applies statistical modelling and comparative analysis techniques to support data-driven clinical decision-making, risk stratification, and treatment optimisation within hypertension management workflows.

• Tableau Story Presentation:View/Download here
• Dataset Used:Download here
• Statistical Output Tables: View here

Data Structure & Analytical Approach

The dataset contains hypertensive patient information, demographic variables, baseline blood pressure measurements, treatment regimens, comorbidity profiles, and follow-up BP control outcomes.

The analysis was conducted using SPSS for statistical modelling and Tableau for dashboard development and executive data storytelling.

Analytical Methods Applied

• Logistic Regression Analysis
• Correlation Analysis
• Comparative Statistical Testing
• Treatment Effectiveness Evaluation
• Risk Stratification Analysis
• Dashboard-Based Trend Exploration

Key Analytical Focus Areas

• Identification of predictors associated with BP control failure
• Evaluation of baseline BP severity impact on outcomes
• Assessment of antihypertensive treatment effectiveness
• Comparison of outcomes across patients with various comorbidities.
• Interpretation of clinical and operational implications of predictive findings

The analysis was designed to simulate real-world healthcare analytics workflows where predictive insights support earlier intervention planning, treatment optimisation, and improved patient management strategies.

Executive Summary

The analysis identified elevated baseline blood pressure, medication adherence, and antihypertensive treatment class as significant predictors of BP control failure at 3-month follow-up.

Patients presenting with severe systolic hypertension (≥160 mmHg) and severe diastolic hypertension (≥110 mmHg) demonstrated extremely high treatment failure rates, with both associations showing strong statistical significance (p < 0.001). High baseline systolic BP emerged as the strongest predictor of BP control failure based on regression analysis.

Medication adherence also demonstrated a significant relationship with BP control outcomes. Failure rates progressively increased with worsening adherence, reaching 98.2% among patients classified with poor medication adherence (χ²(2) = 12.49, p = 0.002).

Treatment outcomes additionally varied significantly across antihypertensive drug classes (χ²(5) = 16.92, p = 0.005). Combination therapy demonstrated the most favourable BP control outcomes overall, with lower failure rates compared with most monotherapy treatment approaches.

Further subgroup analysis showed that combination therapy consistently maintained more favourable BP control outcomes across major comorbidity profiles, including diabetes mellitus, chronic kidney disease (CKD), dyslipidaemia, and obesity.

Overall, the findings suggest that early identification of high-risk hypertensive patients, improved medication adherence strategies, and consideration of combination antihypertensive therapy may improve long-term BP control outcomes and support more proactive hypertension management approaches.

Insights Deep Dive

Severe Baseline Hypertension Strongly Predicts BP Control Failure

• Patients presenting with severe systolic hypertension (≥160 mmHg) and severe diastolic hypertension (≥110 mmHg) demonstrated extremely high BP control failure rates at 3-month follow-up, with failure rates approaching 100% in several high-severity groups.

• Both associations were statistically significant (p < 0.001), indicating that severe baseline hypertension is a strong predictor of BP control failure after treatment initiation.

These findings suggest that patients presenting with markedly elevated baseline BP measurements may require earlier treatment intensification, closer monitoring protocols, and more aggressive hypertension management strategies to reduce the likelihood of persistent uncontrolled blood pressure.

Poor Medication Adherence Was Associated with Progressively Higher Failure Rates

• BP control failure rates increased progressively with worsening medication adherence, reaching 98.2% among patients classified with poor adherence.

• This relationship was statistically significant (χ²(2) = 12.49, p = 0.002), indicating that worsening medication adherence is strongly associated with increased risk of BP control failure after 3 months.

The findings highlight the operational importance of medication counselling, patient education, follow-up systems, and adherence-focused interventions within hypertension management programmes, as poor adherence may substantially reduce treatment effectiveness regardless of prescribed therapy.

Antihypertensive Drug Class Was Associated with BP Control Outcomes

• BP control failure rates varied significantly across antihypertensive drug classes, indicating that treatment class may influence BP control outcomes after 3 months of therapy.

• Combination therapy demonstrated the lowest observed failure rate (78.9%), while monotherapy options generally showed substantially higher failure rates ranging from 86.9% to 100%.

• This association was statistically significant (χ²(5) = 16.92, p = 0.005), suggesting that antihypertensive treatment class is associated with BP control outcomes and may play an important role in treatment effectiveness.

The findings support more careful treatment selection and consideration of earlier combination therapy strategies in hypertensive patients at elevated risk of persistent uncontrolled BP.

Combination Therapy Demonstrated the Lowest BP Control Failure Rate Across Drug Classes

• Failure rates varied significantly across antihypertensive drug classes, with combination therapy demonstrating the lowest BP control failure rate (78.9%) compared with monotherapy options, which generally showed substantially higher failure rates ranging from 86.9% to 100%.

• This association was statistically significant (χ²(5) = 16.92, p = 0.005), suggesting that combination therapy may provide more effective BP control outcomes compared with single-drug treatment approaches.

The findings support consideration of earlier combination antihypertensive therapy in high-risk hypertensive patients where monotherapy may be insufficient for achieving adequate BP control targets.

Combination Therapy Maintained More Favourable Outcomes Across Major Comorbidity Profiles

• Combination therapy consistently demonstrated more favourable BP control outcomes across major comorbidity profiles, including diabetes mellitus, chronic kidney disease (CKD), dyslipidaemia, and obesity.

• Across these clinically complex patient groups, combination therapy showed higher BP control rates and comparatively lower failure rates than most monotherapy treatment classes, suggesting improved treatment effectiveness in patients with coexisting medical conditions.

These findings reinforce the potential value of combination antihypertensive therapy for hypertensive patients with multiple comorbidities who may require more aggressive or comprehensive treatment approaches to achieve adequate BP control outcomes.

Recommendations

• Implement early risk stratification protocols for hypertensive patients presenting with severe baseline systolic and diastolic hypertension.
• Strengthen medication adherence interventions through patient education, follow-up monitoring, and adherence support programmes.
• Consider earlier use of combination antihypertensive therapy in high-risk patients and patients with multiple comorbidities.
• Incorporate predictive risk indicators into routine clinical decision-making to identify patients at elevated risk of BP control failure.
• Conduct further longitudinal and larger-scale studies to validate treatment effectiveness across different patient populations and drug classes.

Assumptions & Caveats

• The analysis assumes that all patient records and blood pressure measurements were accurately recorded and clinically valid.
• BP control outcomes were evaluated using a 3-month follow-up period and may not reflect long-term treatment effectiveness.
• Some treatment subgroups contained relatively small sample sizes, which may affect the stability and generalisability of certain findings.
• The analysis identifies statistical associations and predictive relationships but does not establish direct causation.
• Potential confounding clinical variables not included in the dataset may also influence BP control outcomes.
• Findings should be interpreted within the context of the available dataset and analytical scope.